S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Quidel Stock Forecast, Price & News

+6.46 (+3.26 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $204.49
50-Day Range
MA: $194.59
52-Week Range
Now: $204.49
Volume975,531 shs
Average Volume1.22 million shs
Market Capitalization$8.60 billion
P/E Ratio57.28
Dividend YieldN/A
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Quidel logo


Overall MarketRank

1.45 out of 5 stars

Medical Sector

425th out of 1,558 stocks

Diagnostic Substances Industry

10th out of 28 stocks

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
Current SymbolNASDAQ:QDEL



Sales & Book Value

Annual Sales$534.89 million
Cash Flow$3.41 per share
Book Value$13.44 per share


Net Income$72.92 million


Market Cap$8.60 billion
Next Earnings Date2/10/2021 (Estimated)
+6.46 (+3.26 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QDEL News and Ratings via Email

Sign-up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Quidel (NASDAQ:QDEL) Frequently Asked Questions

How has Quidel's stock been impacted by Coronavirus?

Quidel's stock was trading at $89.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, QDEL shares have increased by 128.0% and is now trading at $204.49.
View which stocks have been most impacted by COVID-19

Is Quidel a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quidel in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Quidel stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QDEL, but not buy additional shares or sell existing shares.
View analyst ratings for Quidel
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Quidel?

Wall Street analysts have given Quidel a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Quidel wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Quidel's next earnings date?

Quidel is scheduled to release its next quarterly earnings announcement on Wednesday, February 10th 2021.
View our earnings forecast for Quidel

How were Quidel's earnings last quarter?

Quidel Co. (NASDAQ:QDEL) posted its quarterly earnings results on Thursday, October, 29th. The company reported $5.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.31 by $1.47. The firm earned $476.10 million during the quarter, compared to analyst estimates of $445.30 million. Quidel had a net margin of 23.61% and a return on equity of 33.86%. Quidel's revenue for the quarter was up 276.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.70 EPS.
View Quidel's earnings history

What guidance has Quidel issued on next quarter's earnings?

Quidel issued an update on its fourth quarter 2020 After-Hours earnings guidance on Thursday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $808-810 million, compared to the consensus revenue estimate of $819.52 million.

What price target have analysts set for QDEL?

5 Wall Street analysts have issued twelve-month price objectives for Quidel's stock. Their forecasts range from $90.00 to $363.00. On average, they anticipate Quidel's share price to reach $219.00 in the next twelve months. This suggests a possible upside of 7.1% from the stock's current price.
View analysts' price targets for Quidel
or view Wall Street analyst' top-rated stocks.

Who are some of Quidel's key competitors?

What other stocks do shareholders of Quidel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quidel investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Square (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM).

Who are Quidel's key executives?

Quidel's management team includes the following people:
  • Mr. Douglas C. Bryant, Pres, CEO & Director (Age 63, Pay $1.07M)
  • Mr. Randall J. Steward, Chief Financial Officer (Age 67, Pay $580.51k)
  • Mr. Robert J. Bujarski, Chief Operating Officer (Age 53, Pay $567.24k)
  • Mr. Ratan S. Borkar, Sr. VP of International Commercial Operations (Age 47, Pay $525.98k)
  • Dr. Werner Kroll, Sr. VP of R&D (Age 64, Pay $566.11k)
  • Ruben Argueta, Director of Investor Relations
  • Ms. Michelle A. Hodges, Sr. VP & Gen. Counsel
  • Mr. Michael Donald Abney Jr., Sr. VP of North American Sales & Distribution (Age 57)
  • Mr. Edward Keith Russell, Sr. VP of Bus. Devel. (Age 53)
  • Ms. Karen Gibson, Sr. VP of Information Systems & Bus. Transformation (Age 59)

What is Quidel's stock symbol?

Quidel trades on the NASDAQ under the ticker symbol "QDEL."

Who are Quidel's major shareholders?

Quidel's stock is owned by a variety of institutional and retail investors. Top institutional investors include Louisiana State Employees Retirement System (0.02%), Crossmark Global Holdings Inc. (0.02%), State of Alaska Department of Revenue (0.01%), Sowell Financial Services LLC (0.01%), Donaldson Capital Management LLC (0.00%) and Bay Rivers Group (0.00%). Company insiders that own Quidel stock include Charles P Slacik, Douglas C Bryant, Edward Keith Russell, Edward L Michael, Karen Gibson, Kenneth F Buechler, Mary Lake Ph D Polan, Matthew Strobeck, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll.
View institutional ownership trends for Quidel

Which major investors are selling Quidel stock?

QDEL stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Quidel company stock in the last year include Edward Keith Russell, Mary Lake Ph D Polan, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, and Werner Kroll.
View insider buying and selling activity for Quidel
or view top insider-selling stocks.

Which major investors are buying Quidel stock?

QDEL stock was purchased by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Donaldson Capital Management LLC, Sowell Financial Services LLC, Bay Rivers Group, Louisiana State Employees Retirement System, and Global Retirement Partners LLC. Company insiders that have bought Quidel stock in the last two years include Douglas C Bryant, Edward L Michael, and Matthew Strobeck.
View insider buying and selling activity for Quidel
or or view top insider-buying stocks.

How do I buy shares of Quidel?

Shares of QDEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quidel's stock price today?

One share of QDEL stock can currently be purchased for approximately $204.49.

How big of a company is Quidel?

Quidel has a market capitalization of $8.60 billion and generates $534.89 million in revenue each year. The company earns $72.92 million in net income (profit) each year or $2.73 on an earnings per share basis. Quidel employs 1,250 workers across the globe.

What is Quidel's official website?

The official website for Quidel is www.quidel.com.

How can I contact Quidel?

Quidel's mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at 858-552-1100 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.